Announced Phase 3 STRIVE-ON Safety Trial Met Primary Endpoint and Provided Clinical Benefit Compared to Orally Administered Nimodipine; New Drug Application (NDA) Submission Anticipated First Half of ...
1d
Announced Phase 3 STRIVE-ON Safety Trial Met Primary Endpoint and Provided Clinical Benefit Compared to Orally Administered Nimodipine; New Drug ...
Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered Nimodipine New Drug Application (NDA) Submission Expected in the First Half of 2025 PRI ...
3d
Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered NimodipineNew Drug Application ...
Hosted on MSN6d
KPMG's Swonk Sees No Fed Cuts Until 2026KPMG Chief Economist Diane Swonk doesn't expect to see a Federal Reserve interest rate cut until the middle of next year. She is on "Bloomberg The Close." ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback